Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma
Immunotherapy has recently become a promising cancer therapy with extensive applications of immune checkpoint inhibitors (ICIs).However, pancreatic ductal adenocarcinoma (PDAC) appears to be kaiser copy stands unresponsive to immunotherapy due to the immunosuppressive microenvironment.Recent studies showed that cancer stem cell marker DCLK1 promote